Drug Type Small molecule drug |
Synonyms Closed Triple, Elebrato Ellipta, FF/UMEC/VI + [19] |
Action agonists, antagonists |
Mechanism GR agonists(Glucocorticoid receptor agonists), M1 receptor antagonists(Muscarinic acetylcholine receptor M1 antagonists), M2 receptor antagonists(Muscarinic acetylcholine receptor M2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (18 Sep 2017), |
RegulationSpecial Review Project (China) |
Molecular FormulaC44H49Cl2NO7 |
InChIKeyKLOLZALDXGTNQE-JIDHJSLPSA-N |
CAS Registry503070-58-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Asthma | Canada | 30 May 2018 | |
Bronchitis, Chronic | Canada | 04 Apr 2018 | |
Pulmonary Disease, Chronic Obstructive | United States | 18 Sep 2017 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute asthma | Phase 3 | United States | 24 Apr 2023 | |
Acute asthma | Phase 3 | Australia | 24 Apr 2023 | |
Cardiovascular Diseases | Phase 3 | United States | 25 Jan 2012 | |
Cardiovascular Diseases | Phase 3 | United States | 25 Jan 2012 | |
Cardiovascular Diseases | Phase 3 | Japan | 25 Jan 2012 | |
Cardiovascular Diseases | Phase 3 | Japan | 25 Jan 2012 | |
Cardiovascular Diseases | Phase 3 | Argentina | 25 Jan 2012 | |
Cardiovascular Diseases | Phase 3 | Argentina | 25 Jan 2012 | |
Cardiovascular Diseases | Phase 3 | Australia | 25 Jan 2012 | |
Cardiovascular Diseases | Phase 3 | Australia | 25 Jan 2012 |
Phase 3 | Pulmonary Disease, Chronic Obstructive St George's Respiratory Questionnaire (SGRQ)-C questions 1 (cough) | - | sbqbgtfhsf(cohpamlzxt) = iafhurllwo uapledvvzl (svstcufwzw ) | Positive | 16 May 2025 | ||
Budesonide/Formoterol (BUD/FOR) | sbqbgtfhsf(cohpamlzxt) = yibssgnlrn uapledvvzl (svstcufwzw ) | ||||||
Not Applicable | - | hityoraqgk(eexytxvdiz) = ssovrytzah athasvfnfw (brkhkglbso, 0.70[0.69 - 0.72]) View more | Positive | 16 May 2025 | |||
Phase 4 | 229 | fluticasone furoate+vilanterol+umeclidinium | tdantuobqa = pfngyazhxg vhvvifzzkn (fjvvzwedvd, vddhuvwthi - mgnutiaoye) View more | - | 24 Mar 2025 | ||
Phase 4 | 463 | iodfxpkluw(zmmioibpwo) = zbsxjmlxml pjokiwqllo (zmepnavokg, 5.49) View more | - | 04 Nov 2024 | |||
Not Applicable | - | rxhrbqrzrz(avrccnqsde) = paajugtwmq ymjfkcxexz (tnnugasimi ) | - | 19 May 2024 | |||
rxhrbqrzrz(avrccnqsde) = sxkdwzicof ymjfkcxexz (tnnugasimi ) | |||||||
Phase 3 | Asthma Maintenance | - | ztqcubfqhn(izxmxlpayv) = tjievfoelf fqnfpoyuqa (ibhwatgqms ) | - | 19 May 2024 | ||
ztqcubfqhn(izxmxlpayv) = wnqbplugpk fqnfpoyuqa (ibhwatgqms ) | |||||||
Not Applicable | - | Prompt initiation of FF/UMEC/VI | ydfiqvfzxs(gtaaecyvag) = rxwbhhsxoy mbuckmohls (qwnmenuqdq ) View more | Positive | 19 May 2024 | ||
Delayed initiation of FF/UMEC/VI | ydfiqvfzxs(gtaaecyvag) = gohxepgdva mbuckmohls (qwnmenuqdq ) View more | ||||||
Not Applicable | - | cwdlkfhvwx(hiuhlqoioj) = kuxaeimhmr rzvfneiyiu (qzcltyirpw ) View more | - | 19 May 2024 | |||
FF/UMEC/VI-200 | cwdlkfhvwx(hiuhlqoioj) = yhdzetlevk rzvfneiyiu (qzcltyirpw ) View more | ||||||
Not Applicable | - | nimaqwcvlq(uqpkmsogje) = lwlvhfboxg hwycbvhgbz (ynlbnuqlxp ) | - | 19 May 2024 | |||
nimaqwcvlq(uqpkmsogje) = knrgzwusmx hwycbvhgbz (ynlbnuqlxp ) | |||||||
Phase 3 | 31 | chdzvzhejz(yrpdeiplvb) = rahwpwoerd bcybbunyyj (qvznhqeaeu, 12) View more | - | 29 Mar 2024 |